Replimune: Second CRL May Have Sealed RP1's Fate - It's Hard To See Positives
Source: SeekingAlpha
2026-04-10 15:30:07 ET
News is breaking today that Replimune Group, Inc.'s ( REPL ) Biologics License Application ("BLA") requesting approval for its drug candidate RP1 (vusolimogene oderparepvec) in the indication of anti-PD-1 failed melanoma has been rejected by the FDA - the second time the FDA has rejected the drug for commercial approval. ...
Read the full article on Seeking Alpha
For further details see:
Replimune: Second CRL May Have Sealed RP1's Fate - It's Hard To See Positives
Replimune Group Inc.
NASDAQ: REPL
REPL Trading
28.78% G/L:
$5.19 Last:
9,599,164 Volume:
$3.99 Open:
REPL Latest News
REPL Stock Data
$646,543,607
51,607,887
0.33%
61
N/A
Biotechnology & Life Sciences
Healthcare
US
Woburn
